Overview

Clinical Study for the Evaluation of Safety and Tolerability of SCAI-005 Eye Drops

Status:
COMPLETED
Trial end date:
2025-09-04
Target enrollment:
Participant gender:
Summary
To assess the single-dose and multiple-dose pharmacokinetics (PK), safety and tolerability of SCAI-005 eyedrops(axitinib) in healthy volunteers
Phase:
PHASE1
Details
Lead Sponsor:
SCAI Therapeutics